Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 11/20 | 0.76 |
| ▸ | SLCO1B3 | Q9NPD5 | 8/20 | 0.76 |
| ▸ | SLCO1B1 | Q9Y6L6 | 8/20 | 0.76 |
| ▸ | USP2 | O75604 | 7/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.76 |
| ▸ | TP53 | P04637 | 4/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15414716 | 0.86 | CYP3A4 (1.00) | CYP3A4SLCO1B3SLCO1B1USP2SMN1; SMN2 | |
| SCHEMBL7977568 | 0.85 | CYP3A4 (0.75) | CYP3A4SLCO1B3SLCO1B1USP2SMN1; SMN2 | |
| SCHEMBL7952357 | 0.85 | CYP3A4 (0.68) | CYP3A4SLCO1B3SLCO1B1USP2SMN1; SMN2 | |
| SCHEMBL7973092 | 0.84 | CYP3A4 (0.76) | CYP3A4SLCO1B3SLCO1B1USP2SMN1; SMN2 | |
| SCHEMBL7963869 | 0.84 | CYP3A4 (0.76) | CYP3A4SLCO1B3SLCO1B1USP2SMN1; SMN2 | |
| SCHEMBL9973651 | 0.83 | CYP3A4 (0.77) | CYP3A4SLCO1B3SLCO1B1USP2SMN1; SMN2 | |
| SCHEMBL9973665 | 0.83 | CYP3A4 (0.69) | CYP3A4SLCO1B3SLCO1B1USP2SMN1; SMN2 | |
| SCHEMBL9973664 | 0.82 | CYP3A4 (0.69) | CYP3A4SLCO1B3SLCO1B1USP2SMN1; SMN2 | |
| SCHEMBL7964651 | 0.81 | CYP3A4 (0.73) | CYP3A4SLCO1B3SLCO1B1USP2SMN1; SMN2 | |
| SCHEMBL7952355 | 0.80 | CYP3A4 (0.68) | CYP3A4SLCO1B3SLCO1B1USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170216319-A1 | Treating Various Disorders Using TrkB Agonists | UNIV EMORY (US) | 2017-08-03 | — | — | US | disclosed |
| US-20170216319-A1 | Treating Various Disorders Using TrkB Agonists | UNIV EMORY (US) | 2017-08-03 | — | — | US | disclosed |
| US-20160213691-A1 | Treating Various Disorders Using TrkB Agonists | UNIV EMORY (US) | 2016-07-28 | — | — | US | disclosed |
| US-20160213691-A1 | Treating Various Disorders Using TrkB Agonists | UNIV EMORY (US) | 2016-07-28 | — | — | US | disclosed |
| US-8609870-B2 | Treating various disorders using TrkB agonists | EMORY UNIVERSITY (US) | 2013-12-17 | — | — | US | disclosed |
| US-8609870-B2 | Treating various disorders using TrkB agonists | EMORY UNIVERSITY (US) | 2013-12-17 | — | — | US | disclosed |
| US-20130131157-A1 | TREATING VARIOUS DISORDERS USING TRKB AGONISTS | EMORY UNIVERSITY (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131157-A1 | TREATING VARIOUS DISORDERS USING TRKB AGONISTS | EMORY UNIVERSITY (US) | 2013-05-23 | — | — | US | disclosed |
| US-20120277222-A1 | TREATING VARIOUS DISORDERS USING TRKB AGONISTS | EMORY UNIVERSITY (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120277222-A1 | TREATING VARIOUS DISORDERS USING TRKB AGONISTS | EMORY UNIVERSITY (US) | 2012-11-01 | — | — | US | disclosed |
| US-8203009-B2 | Neurotrophic activity of deoxygedunin | EMORY UNIVERSITY (US) | 2012-06-19 | — | — | US | disclosed |
| US-8203009-B2 | Neurotrophic activity of deoxygedunin | EMORY UNIVERSITY (US) | 2012-06-19 | — | — | US | disclosed |
| US-20110144096-A1 | TREATING VARIOUS DISORDERS USING TRKB AGONISTS | EMORY UNIVERSITY (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110144096-A1 | TREATING VARIOUS DISORDERS USING TRKB AGONISTS | EMORY UNIVERSITY (US) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144096-A1 | TREATING VARIOUS DISORDERS USING TRKB AGONISTS | NTRK2, BDNF, NTRK1 | CYP3A4 1543/4885SLCO1B3 2965/4885SLCO1B1 3410/4885 |
| US-20120277222-A1 | TREATING VARIOUS DISORDERS USING TRKB AGONISTS | NTRK2, BDNF, NTRK1 | CYP3A4 1343/4885SLCO1B3 2870/4885SLCO1B1 3251/4885 |
| US-20130131157-A1 | TREATING VARIOUS DISORDERS USING TRKB AGONISTS | NTRK2, BDNF, NTRK1 | CYP3A4 1343/4885SLCO1B3 2870/4885SLCO1B1 3251/4885 |
| US-20170216319-A1 | Treating Various Disorders Using TrkB Agonists | NTRK2, BDNF, NTRK1 | CYP3A4 1343/4885SLCO1B3 2870/4885SLCO1B1 3251/4885 |
| US-20160213691-A1 | Treating Various Disorders Using TrkB Agonists | NTRK2, BDNF, NTRK1 | CYP3A4 1343/4885SLCO1B3 2870/4885SLCO1B1 3251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.